NCT06723080View on ClinicalTrials.gov

Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

PHASE3RecruitingINTERVENTIONAL
Enrollment

480

Participants

Timeline

Start Date

December 30, 2024

Primary Completion Date

August 30, 2027

Study Completion Date

August 30, 2027

Conditions
Moderate to Severe Atopic Dermatitis
Interventions
DRUG

VC005 low dose group

VC005 low dose group repeat administration

DRUG

VC005 high dose group

VC005 high dose group repeat administration

DRUG

VC005 Placebo group

VC005 Placebo group repeat administration

Trial Locations (1)

210042

RECRUITING

Chinese Academy of Medical Sciences Hospital for Skin Diseases, Nanjing

All Listed Sponsors
lead

Jiangsu vcare pharmaceutical technology co., LTD

INDUSTRY